Oncotarget | Kinase activity in renal cell carcinoma, benign renal tissue and in response to tyrosine kinase inhibitors
Researchers identified differences in PTK activity between normal and cancer kidney tissue, with Src family kinases and PI3K pathways exhibiting high activity. Ex vivo treatment of clear cell RCC with TKIs revealed that tivozanib and cabozantinib were more potent inhibitors than sunitinib or pazopanib.